Lutz Prof. Dr. Gissmann

Lutz Prof. Dr. Gissmann's AcademicInfluence.com Rankings

Biology

#7244

World Rank

#10137

Historical Rank

Virology

#150

World Rank

#155

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Lutz Prof. Dr. Gissmann Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lutz Prof. Dr. Gissmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. (1983) (1940)
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells (1985) (1493)
Chapter 1: HPV in the etiology of human cancer. (2006) (1300)
A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. (1984) (1270)
Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. (1983) (853)
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles (1993) (640)
The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. (1985) (492)
Bead-Based Multiplex Genotyping of Human Papillomaviruses (2006) (484)
Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma (1982) (442)
Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. (1987) (431)
Human papillomavirus type‐16‐related DNA in genital Bowen's disease and in bowenoid papulosis (1983) (389)
HPV in the etiology of human cancer (2006) (352)
TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 161 (2007) (344)
Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. (1987) (341)
Transcriptional regulation of the human papillomavirus‐16 E6‐E7 promoter by a keratinocyte‐dependent enhancer, and by viral E2 trans‐activator and repressor gene products: implications for cervical carcinogenesis. (1987) (329)
Molecular cloning of viral DNA from human genital warts (1981) (314)
Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. (1988) (297)
Analysis of oral papillomas, leukoplakias, and invasive carcinomas for human papillomavirus type related DNA. (1985) (292)
Partial characterization of viral DNA from human genital warts (condylomata acuminata) (1980) (289)
Human papilloma viruses (HPV): characterization of four different isolates. (1977) (264)
Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. (1989) (252)
Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA (1982) (251)
Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women (1987) (240)
Presence of human papillomavirus in genital tumors. (1984) (236)
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. (2004) (201)
Synthetic Double-Stranded RNAs Are Adjuvants for the Induction of T Helper 1 and Humoral Immune Responses to Human Papillomavirus in Rhesus Macaques (2009) (193)
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes (2007) (188)
Virus-like particles as vaccines and vessels for the delivery of small molecules. (2004) (182)
Identification of Human Papillomavirus in Cervical Swabs by Deoxyribonucleic Acid In Situ Hybridization (1984) (176)
A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates. (1984) (175)
Papillomavirus capsid binding and uptake by cells from different tissues and species (1995) (172)
Characterization of human papillomavirus type 13 from focal epithelial hyperplasia Heck lesions (1983) (168)
Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. (1992) (148)
E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice (2011) (147)
Immune response to human papillomavirus 16 L1E7 chimeric virus‐like particles: Induction of cytotoxic T cells and specific tumor protection (1999) (146)
Bowenoid papulosis. Presence of human papillomavirus (HPV) structural antigens and of HPV 16-related DNA sequences. (1985) (146)
Papillomavirus infection of the anogenital region: correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature. (1985) (142)
Papillomaviruses and Human Disease (1987) (136)
Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3) (2007) (132)
Antibodies against Early Proteins of Human Papillomaviruses as Diagnostic Markers for Invasive Cervical Cancer (1998) (132)
Human papilloma virus DNA: physical mapping and genetic heterogeneity. (1976) (132)
Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA. (1983) (131)
Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer (2014) (129)
Papillomavirus infections and human genital cancer. (1981) (128)
Chimeric papillomavirus-like particles. (1997) (124)
A high frequency of human papillomavirus DNA sequences in cervical carcinomas of indian women as revealed by southern blot hybridization and polymerase chain reaction (1992) (123)
Biological activity of probable/possible high‐risk human papillomavirus types in cervical cancer (2013) (118)
Correlation between human papillomavirus (HPV) type and histology of warts. (1982) (117)
Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes (2001) (115)
Human Papillomavirus Type 16 L1 Capsomeres Induce L1-Specific Cytotoxic T Lymphocytes and Tumor Regression in C57BL/6 Mice (2003) (110)
Human Papillomaviruses in Women With a History of Abnormal Papanicolaou Smears and in Their Male Partners (1987) (106)
Sensitivity of the cytologic diagnosis of cervical condyloma in comparison with HPV‐DNA hybridization studies (1987) (99)
Skin human papillomavirus type 38 alters p53 functions by accumulation of ΔNp73 (2006) (97)
Presence of human papillomavirus type‐16 and type‐18 DNA sequences and their expression in cervical cancers and cell lines from japanese patients (1986) (96)
Rearranged HPV 16 molecules in an anal and in a laryngeal carcinoma (1986) (96)
Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears (1992) (96)
Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. (2002) (95)
Human papilloma viruses and cancer. (1975) (93)
Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. (1997) (89)
Viruses in the etiology of human genital cancer. (1984) (88)
Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. (1999) (88)
Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. (2009) (87)
Molecular cloning of two new HPV types (HPV 37 and HPV 38) from a keratoacanthoma and a malignant melanoma (1986) (86)
Characterization of a human papillomavirus from epidermodysplasia verruciformis lesions of a patient from upper‐volta (1981) (85)
Chromosomal integration sites of human papillomavirus DNA in three cervical cancer cell lines mapped by in situ hybridization (1987) (84)
Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. (2009) (83)
Beta HPV38 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin carcinogenesis in mice (2018) (81)
Human papillomavirus type 16 related DNA in an anaplastic carcinoma of the lung (1985) (80)
Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. (2006) (80)
Skin Hyperproliferation and Susceptibility to Chemical Carcinogenesis in Transgenic Mice Expressing E6 and E7 of Human Papillomavirus Type 38 (2005) (79)
Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer (2008) (77)
Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate (2012) (77)
HUMAN PAPILLOMAVIRUS GENOMES IN PENILE SMEARS OF HEALTHY MEN (1986) (77)
HPV16 L1E7 chimeric virus‐like particles induce specific HLA‐restricted T cells in humans after in vitro vaccination (2001) (76)
Herpes simplex virus‐induced amplification of SV40 sequences in transformed Chinese hamster embryo cells (1983) (76)
Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression (2003) (75)
Comparative Analysis of Transforming Properties of E6 and E7 from Different Beta Human Papillomavirus Types (2011) (75)
Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. (2008) (72)
Lymphotropic papovaviruses isolated from African green monkey and human cells (1979) (70)
Partial characterization of a new type of bovine papilloma viruses. (1979) (70)
Human papillomaviruses and genital cancer. (1992) (70)
Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk (1993) (69)
Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients. (1993) (69)
Subclinical human papillomavirus infections in male sexual partners of female carriers. (1988) (68)
Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. (1992) (68)
Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. (2010) (68)
Analysis of Modified Human Papillomavirus Type 16 L1 Capsomeres: the Ability To Assemble into Larger Particles Correlates with Higher Immunogenicity (2009) (65)
Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1 (2006) (65)
Geographical dependence of sequence variation in the E7 gene of human papillomavirus type 16. (1992) (64)
Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. (2004) (64)
Association of rare human papillomavirus types with genital premalignant and malignant lesions. (1998) (63)
Mastomys natalensis papilloma virus (MnPV), the causative agent of epithelial proliferations: characterization of the virus particle. (1978) (62)
Distribution pattern of human papilloma virus 16 genome in cervical neoplasia by molecular in situ hybridization of tissue sections (1987) (62)
Subclinical Epstein-Barr virus infection of both the male and female genital tract--indication for sexual transmission. (1992) (61)
Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae. (2000) (61)
Interferon treatment of human genital papillomavirus infection: Importance of viral type (1987) (60)
Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: anti-proliferative effects on HPV 16-transformed cells. (1999) (58)
Human papillomavirus type 48 (1989) (57)
A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. (2001) (57)
The nucleotide sequence and genome organization of human papilloma virus type 11. (1986) (57)
Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors (1994) (55)
Enhanced papillomavirus-like particle production in insect cells. (2009) (55)
An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. (2006) (54)
Helicobacter pylori antibody patterns in Germany: a cross-sectional population study (2014) (53)
General primer polymerase chain reaction in combination with sequence analysis for identification of potentially novel human papillomavirus genotypes in cervical lesions (1992) (53)
Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. (1997) (52)
Early phase in the infection of cultured cells with papillomavirus virions. (1995) (52)
Identification of seroreactive regions of the human papillomavirus type 16 protein E4, E6, E7 and L1. (1990) (51)
Detection of infectious adeno-associated virus particles in human cervical biopsies. (1998) (50)
Amplification of bovine papillomavirus DNA by N-methyl-N'-nitro-N-nitrosoguanidine, ultraviolet irradiation, or infection with herpes simplex virus. (1989) (48)
Human papillomaviruses and carcinogenesis: well-established and novel models. (2017) (47)
Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. (2008) (47)
Persistence and expression of human papillomavirus DNA in genital cancer. (1986) (47)
Serologic response to the E4, E6, and E7 proteins of human papillomavirus type 16 in pregnant women. (1998) (44)
Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. (2012) (44)
Regulation of human papillomavirus type 18 in vivo: effects of estrogen and progesterone in transgenic mice. (1997) (43)
Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation. (1996) (40)
The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer. (1996) (40)
[Breast cancer in the early stage]. (2012) (39)
Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. (2006) (39)
Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. (2000) (38)
Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles. (2008) (37)
Sequences required for the nuclear targeting and accumulation of human papillomavirus type 6B L2 protein. (1995) (37)
Enhancement of immunogenicity of a therapeutic cervical cancer DNA‐based vaccine by co‐application of sequence‐optimized genetic adjuvants (2009) (37)
Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. (2000) (36)
Therapeutic Vaccines for Human Papillomaviruses (2001) (36)
Identification of human papillomavirus type 16 E7 protein by monoclonal antibodies. (1987) (35)
IκB Kinase β Promotes Cell Survival by Antagonizing p53 Functions through ΔNp73α Phosphorylation and Stabilization (2011) (34)
E7-specific cytotoxic T cell tolerance in HPV-transgenic mice (1999) (34)
Potato Virus X Coat Protein Fusion to Human Papillomavirus 16 E7 Oncoprotein Enhance Antigen Stability and Accumulation in Tobacco Chloroplast (2009) (34)
Interferon-γ Enhances Susceptibility of Cervical Cancer Cells to Lysis by Tumor-Specific Cytotoxic T Cells (1997) (33)
Immunologic responses to human papillomavirus infection. (1996) (33)
Detection of Epstein-Barr virus-DNA in tongue epithelium of human immunodeficiency virus-infected patients. (1991) (32)
Cell-type-specific activity of the human papillomavirus type 18 upstream regulatory region in transgenic mice and its modulation by tetradecanoyl phorbol acetate and glucocorticoids (1993) (32)
Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. (2005) (32)
Partial characterization of the proteins of human papilloma viruses (HPV) 1-3. (1977) (32)
Growth-regulating functions of human papillomavirus early gene products in cervical cancer cells acting dominant over enhanced epidermal growth factor receptor expression. (1990) (31)
Nucleic acid hybridization for the detection of viral genomes. (1983) (30)
Comparison of ELISA and western blotting for human papillomavirus type 16 E7 antibody determination. (1991) (30)
Molecular cloning and characterization of human papillomavirus type 7 DNA. (1986) (30)
Cloning of Papillomavirus DNA (1985) (29)
Detection of human papillomavirus type 16 DNA and of antibodies to human papillomavirus type 16 proteins in children. (1997) (29)
[Recurrent respiratory papillomatosis: indication for HPV vaccination?]. (2009) (29)
New Approaches to Prophylactic Human Papillomavirus Vaccines for Cervical Cancer Prevention (2011) (29)
Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia. (2009) (29)
Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesis. (2013) (29)
T Cell Response to Human Papillomavirus 16 E7 in Mice: Comparison of Cr Release Assay, Intracellular IFN-γ Production, ELISPOT and Tetramer Staining (2003) (29)
Papillomaviruses and human oncogenesis (1992) (28)
Human papillomavirus type 18 E6*, E6, and E7 protein synthesis in cell-free translation systems and comparison of E6 and E7 in vitro translation products to proteins immunoprecipitated from human epithelial cells (1991) (28)
Epstein-Barr virus (P3HR-1) defective DNA codes for components of both the early antigen and viral capsid antigen complexes. (1984) (27)
Activation of Dendritic Cells and Induction of T Cell Responses by Hpv 16 L1/E7 Chimeric Virus-Like Particles are Enhanced by Cpg ODN or Sorbitol (2004) (25)
Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens. (1997) (25)
Correlation between content of viral DNA and evidence of mature virus particles in HPV-1, HPV-4, and HPV-6 induced virus acanthomata. (1983) (25)
Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia (1991) (25)
Calcium is required in reassembly of bovine papillomavirus in vitro. (1998) (25)
Prophylactic DNA immunization against multiple papillomavirus types. (2007) (24)
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. (2010) (24)
Linking HPV to cancer. (1989) (24)
Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups. (1996) (24)
Prevalence of respiratory syncytial virus infection in Riyadh during the winter season 2007-2008 and different risk factors impact (2009) (23)
Novel ß-HPV49 Transgenic Mouse Model of Upper Digestive Tract Cancer. (2016) (23)
HPV-16-RELATED BOWENOID PAPULOSIS (1985) (23)
Human Papillomavirus-Specific Immune Therapy: Failure and Hope (2010) (23)
Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. (2006) (23)
Sense and antisense transcripts of human papillomavirus type 16 in cervical cancers. (1992) (22)
HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs). (2004) (22)
The E6 variant proteins E6I-E6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53. (1996) (22)
Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly. (2006) (22)
Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors (2009) (21)
Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro. (1996) (20)
NC37-R1 Epstein-Barr virus (EBV): a possible recombinant between intracellular NC37 viral DNA and superinfecting P3HR-1 EBV. (1980) (20)
Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints (2008) (20)
Transcutaneous immunization in mice: Induction of T‐helper and cytotoxic T lymphocyte responses and protection against human papillomavirus–induced tumors (2006) (19)
The HPV16 transcriptome in cervical lesions of different grades. (2011) (19)
Identification of human papillomavirus-16 E6 variation in cervical cancer and their impact on T and B cell epitopes. (2015) (19)
Human papillomavirus type 53 (1989) (18)
A Long Way: History of the Prophylactic Papillomavirus Vaccine (2007) (18)
NF‐κ B‐dependent upregulation of ICAM‐1 by HPV16‐E6/E7 facilitates NK cell/target cell interaction (2011) (18)
Major histocompatibility complex and human papillomavirus type 16 E7 expression in high-grade vulvar lesions. (1993) (18)
HPV vaccines: preclinical development. (2009) (18)
A general purification protocol for E7 proteins from "high- and low-risk" human papillomavirus types expressed in the yeast Schizosaccharomyces pombe. (1997) (18)
Human papillomavirus DNA in genital tumours. (1984) (16)
Identification of B-Cell Epitopes on Virus-Like Particles of Cutaneous Alpha-Human Papillomaviruses (2009) (16)
Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy (2015) (16)
A human papillomavirus closely related to HPV 13 found in a focal epithelial hyperplasia lesion (Heck disease) (2004) (15)
BOWENOID DYSPLASIA IN HUMAN PAPILLOMAVIRUS-16 DNA POSITIVE FLAT CONDYLOMAS DURING INTERFERON-β TREATMENT (1984) (15)
The CXXC Zn binding motifs of the human papillomavirus type 16 E7 oncoprotein are not required for its in vitro transforming activity in rodent cells (1998) (15)
The therapeutic vaccine: is it feasible? (2009) (15)
Secretion of heterologous proteins from Schizosaccharomyces pombe using the homologous leader sequence of pho1+ acid phosphatase. (1998) (14)
Molecular Cloning ofViral DNA fromHumanGenital Warts (1981) (14)
Design of a Highly Effective Therapeutic HPV16 E6/E7-Specific DNA Vaccine: Optimization by Different Ways of Sequence Rearrangements (Shuffling) (2014) (14)
Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. (1997) (14)
Expression of the HPV11 E2 gene in transgenic mice does not result in alterations of the phenotypic pattern (2008) (12)
Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients (1994) (12)
Association of HPV with human genital tumors. (1985) (12)
Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: In-silico & in-vivo insight to vaccine development (2015) (11)
The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice. (2017) (11)
Molecular cloning and partial nucleotide sequence of human papillomavirus type 1a DNA. (1982) (10)
Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type-specific reaction of anti-HPV 16 antibodies. (1992) (10)
Immunization against human papillomavirus infection and associated neoplasia. (2000) (10)
The Worldwide Perspective on Human Papillomavirus and Cervical Cancer (2012) (10)
Immune Response to Genital Papillomavirus Infections in Women Prospects for the Development of a Vaccine against Cervical Cancer (1993) (10)
Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells. (2000) (9)
Identification of papillomaviral DNA sequences in hairless mouse tumours induced by ultraviolet irradiation. (1989) (9)
Inverted repetitive sequences in human papilloma virus 1 (HPV-1) DNA. (1977) (9)
An amplification unit in human melanoma cells showing partial homology with sequences of human papillomavirus type 9 and with nuclear antigen 1 of the Epstein-Barr virus. (1987) (9)
Analysis of the biological role of human papilloma virus (HPV)-encoded transcripts in cervical carcinoma cells by antisense RNA. (1987) (9)
Demonstration of HPV-16 genomes in the nuclei of cervix carcinoma cells. (1985) (9)
Tumor prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination (2014) (9)
Seroreactivity against HPV 16 E4 and E7 proteins in renal transplant recipients and pregnant women. (1992) (9)
Comparison of DNA- and mRNA-Transfected Mouse Dendritic Cells as Potential Vaccines against the Human Papillomavirus Type 16 associated Oncoprotein E7 (2008) (9)
Heterogeneity of human papilloma viruses. (1978) (8)
Development of prophylactic HPV vaccines. (2007) (8)
The E7 protein of human papillomavirus (HPV) type 16 expressed by recombinant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients. (1996) (8)
The human papillomavirus type 11 upstream regulatory region triggers hair-follicle-specific gene expression in transgenic mice. (1999) (8)
Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in culture (2005) (8)
Occurrence of HPV genomes in penile smears of healthy men (2004) (7)
Cancer susceptibility of beta HPV49 E6 and E7 transgenic mice to 4-nitroquinoline 1-oxide treatment correlates with mutational signatures of tobacco exposure. (2019) (7)
The type of human papillomavirus present in cervical infections can be determined by the occurrence of specific marker proteins. (1986) (7)
Measurement of cell-mediated immunity against bovine papilloma virus by lymphoproliferative reactions. (1987) (7)
Highlights of the 27th International Papillomavirus Conference and Clinical Workshop: part 2: applied clinical science (2012) (7)
Interferon therapy for bronchial papillomatosis controlled by papillomavirus-DNA hybridization. (1985) (7)
Papilloma Viruses and Human Cancer (1991) (6)
Experimental evidence on oncogenicity of papillomaviruses. (1989) (6)
HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in HPV-based cervical cancer precursor screening. (2015) (6)
Sequence variation in the E7 gene of human papillomavirus type 18 in tumor and non‐tumor patients and antibody response to a conserved seroreactive epitope (1993) (6)
Highlights of the 27th International Papillomavirus Conference and Clinical Workshop: part 1 (2011) (6)
Detection of individual virus-infected cells by filter in situ hybridization. (1988) (6)
Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. (2015) (6)
Human papillomavirus early gene products and maintenance of the transformed state of cervical cancer cells in vitro. (1989) (5)
HUMAN PAPILLOMAVIRUS PRECEDING INTRAEPITHELIAL NEOPLASIA IN SERIAL CERVICAL SMEARS (1988) (5)
Convergent infections: human papillomavirus and human immunodeficiency virus. (1994) (5)
Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018. (2014) (5)
Molecular cloning, analysis, and chromosomal localization of a mouse genomic sequence related to the human papillomavirus type 18 E5 region (1992) (5)
[Demonstration and organizational structure of the DNA of human papillomaviruses in laryngeal and hypopharyngeal carcinomas]. (1987) (4)
Isolation and characterization of a rod-shaped bacteriocin from a strain of Rhizobium. (1975) (4)
Linking human papillomaviruses to cervical cancer: a long and winding road. (2006) (4)
Immune response to papillomavirus infections. (1989) (4)
[Prevention of HPV-associated neoplasias by vaccination - short version of the German S3 (level 3) guideline]. (2010) (4)
Physical characterization of the deoxyribonucleic acids of different human papilloma viruses (HPV) (1978) (4)
Correction: E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice (2016) (3)
Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns (Cancer Research (2010) 70, (249-56) DOI: 10.1158/0008-5472.CAN-09- 2514) (2010) (3)
Detection of Antibodies Against Early Proteins of Human Papillomavirus Type 16 in Human Sera (1990) (3)
Highlights of the 27th International Papillomavirus Conference and Clinical Workshop: part 3: epidemiology and public health (2012) (3)
Vaccination against HPV-Associated Neoplasias (2014) (3)
Diagnosis of Papillomavirus Infection by Nucleic Acid Hybridization (1985) (3)
Cervical Cancer (1959) (2)
Human papillomavirus type 33 DNA and E6-E7 transcripts in late passages of the UT-DEC-1 vaginal keratinocyte cell line. (1998) (2)
Immunological Aspects of the E6 and E7 Oncogenes: Tools for Diagnosis and Therapeutic Intervention (1997) (2)
Epidemiology, aetiology and prevention of carcinoma of the cervix (1999) (2)
[Clinical significance of human papilloma virus (HPV) infections of the lower genital tract]. (1986) (2)
Human Papillomavirus and Immunosuppression (1995) (1)
Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model. (2016) (1)
Papillomavirus Type 16 by the Cervical Cancer-Associated Human TLR9 Expression and Function Is Abolished (2007) (1)
[Detection of papillomavirus capsid antigens and human papillomavirus 16-related DNA in Bowenoid papulosis and Bowen disease]. (1984) (1)
[Vaccination against HPV-associated neoplasias]. (2014) (1)
Prophylactic HPV Vaccines (2011) (1)
International Symposium: Skin Carcinogenesis in Man and in Experimental Models (1992) (1)
Efficient Self-Assembly ofHumanPapillomavirus Type16LI andL1-L2intoVirus-Like Particles (1993) (1)
Vaccine formulations comprising papilloma virus capsomere and methods of use thereof (1998) (1)
Cervical lesions express the suspected transforming proteins of HPV (1987) (0)
Mechanisms of Carcinogenesis (1986) (0)
seroreactive regions along e1 and e2 proteins of HPV16. (1992) (0)
[Intracutaneous test for detection of cellular immune reactions to HPV-16 proteins in patients with CIN]. (1991) (0)
Recurrent respiratory papillomatosis (2009) (0)
[Condylomas--evidence for the involvement of papillomaviruses in the development of cervical cancer]. (1985) (0)
Monoclonal antibodies against e7-protein of human papillomavirus type 16, process for their production and their use (1987) (0)
Human Papillomavirus Type 16 L1 Capsomeres Induce L1-Speciﬁc Cytotoxic T Lymphocytes and Tumor Regression in C57BL/6 Mice† (2003) (0)
Contents, Vol. 31, Supplement 2, 1991 (1991) (0)
B-Lymphotropic Papovavirus (LPV)—Infections of Man? (1981) (0)
Human Papillomavirus and Cervical Cancer (2007) (0)
Preclinical investigation of DNA immunization with a rearranged human papillomavirus type 16 (HPV16) E7 oncogene (2004) (0)
Antibody Immune Response to Early and Late Viral Proteins in Human Papilloma Virus ( HPV ) Infection and Associated Diseases (2002) (0)
HPV VACCINATION IN THE TREATMENT OF CERVICAL CANCER (2003) (0)
Krebsprävention durch Vakzination (1998) (0)
I (cid:1) B Kinase (cid:2) Promotes Cell Survival by Antagonizing p53 Functions through (cid:3) Np73 (cid:4) Phosphorylation and Stabilization (cid:1) (2011) (0)
The currently licensed human papillomavirus (HPV) vac- cines are safe and highly effective at preventing HPV infection for a select number of papillomavirus types, thus decreasing the incidence of precursors to cervical (2012) (0)
[Bowenoid papulosis and carcinoma in situ of the cervix uteri in sex partners. An example of the transmissibility of HPV-16 infection]. (1985) (0)
Immune Biology of Human Papillomaviruses: Implications for Vaccine Development (2012) (0)
The Discovery of HPV and its Clinical Implications (2010) (0)
Immune therapy against papillomavirus-related tumors in humans (2006) (0)
Erratum: Seroreactivity against HPV 16 E4 and E7 proteins in renal transplant recipients and pregnant women (The Journal of Investigative Dermatology (Vol. 98, Nr. 3, March 1992, p. 389)) (1992) (0)
Antibodies to the Human Papillomavirus 16 and 18 E7 Proteins: A Possible Diagnostic Marker for Cervical Cancer (1992) (0)
Tumor prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination (2014) (0)
Primary Prevention by Vaccination (2012) (0)
Papilloma virus capsomeres vaccine formulations and uses thereof (1998) (0)
[Prophylactic and therapeutic HPV immunization]. (2007) (0)
Immune response of mice following human papilloma virus 6b L1 DNA immunization (1996) (0)
Induction of hpv 16 e7 peptide specific CTLs by CD80 transduced HPV 16 positive cervical carcinoma cells (1996) (0)
Targeted Expression oftheE6andE7Oncogenes ofHuman Papillomavirus Type16intheEpidermis ofTransgenic MiceElicits Generalized Epidermal Hyperplasia Involving Autocrine Factors (1994) (0)
Chimeric virus-like particles or chimeric capsomeres of BPV (1999) (0)
Transformation by high-risk HPV is the consequence of persistent infections (2010) (0)
[Insensitivity of defective lysogenic Rhizobium lupini strains to homologous phage-like bacteriocins]. (1974) (0)
HPV biology and implications in gynecological malignancies (2012) (0)
Humoral Immune Response to Genital Human Papillomavirus Infections (1994) (0)
6 – DISEASE STATES AND VACCINES: SELECTED CASES: PART J. Human Papillomaviruses1 (2003) (0)
Prophylactic vaccines against cervical cancer (2006) (0)
Contents Vol. 45, 2002 (2003) (0)
[Sexual transmissibility of papillomaviruses]. (1985) (0)
[Occurrence of defective lysogeny in Rhizobium lupini]. (1974) (0)
Interleukin-2, IL-7, and IL-12 enhance immunogenicity of CD80 expressing tumor vaccines (1996) (0)
HumanPapillomavirus Type18E6*,E6,andE7Protein Synthesis inCell-Free Translation Systems andComparison ofE6andE7 InVitro Translation Products toProteins Immunoprecipitated fromHumanEpithelial Cells (1991) (0)
Immunogenic regions on the E7 protein of the human type papillomvierus 16 (1989) (0)
[Detection of various papilloma virus types in cytologic smears of precancerous conditions and cancers of the uterine cervix]. (1985) (0)
Polypeptide having immunogenic properties and altered biological functions of a protein (1998) (0)
Subject Index, Vol. 12, 1979 (1979) (0)
Epidemiology of mucosotropic papillomaviruses (2012) (0)
Human Papillomaviruses as an Essential Factor for the Development of Cervical Cancer (1988) (0)
Papilloma virus capsomeres vaccine-formulations and their uses (1998) (0)
CancerWorldwide Perspective on Human Papillomavirus and Cervical (2012) (0)
Formulations and methods of use of capsomer papilloma virus vaccine. (1998) (0)
Current state of preventive vaccinations (2001) (0)
Papilloma virus particle, fusion proteins and methods for their preparation (1995) (0)
Vector for the activation of the immune system associated with papillomavirus thereof or sequences cells (1996) (0)
[Urogenital and anal papillomavirus infections]. (1986) (0)
Vaccine formulations containing capsomeres human papilloma virus and methods of use. (1998) (0)
[Possibilities of vaccination against HPV infections in cervix carcinoma]. (2001) (0)
HPV - infection, HIV - infection and other STD's in Tanzanian female patients of childbearing age (1990) (0)
Antiviral drug developments (2003) (0)
“HPV in the Etiology of Human Cancer” (2006) by Nubia Muñoz, Xavier Castellsagué, Amy Berrington de González, and Lutz Gissmann (2022) (0)
Current Cancer Research 1986 (1986) (0)
Cell-Type-Specific Activity oftheHumanPapillomavirus Type18Upstream Regulatory RegioninTransgenic MiceandItsModulation byTetradecanoyl (1993) (0)
Dendritic cells transduced by a rearranged HPV-16 E7 DNA vaccine induces in vitro E7 wildtype-specific human T cells (2005) (0)
High-efficiency formation of papilloma virus-like particles (1995) (0)
Seroreactive regions of the proteins E1 and E2 of HPV 16 (1992) (0)
Subject Index Vol. 45, 2002 (2003) (0)
Seroreactive region on hpv 16 proteins e1 and e2 (1992) (0)
Polyvalent vaccine against diseases caused by papilloma viruses, processes for their preparation and their use (2001) (0)
Contents, Vol. 12, 1979 (1979) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lutz Prof. Dr. Gissmann?

Lutz Prof. Dr. Gissmann is affiliated with the following schools:

Lutz Prof. Dr. Gissmann's Academic­Influence.com Rankings

Why Is Lutz Prof. Dr. Gissmann Influential?

Lutz Prof. Dr. Gissmann's Published Works

Published Works

What Schools Are Affiliated With Lutz Prof. Dr. Gissmann?

Lutz Prof. Dr. Gissmann's AcademicInfluence.com Rankings